Bradley Canino
Stock Analyst at Guggenheim
(4.43)
# 1,161
Out of 4,520 analysts
283
Total ratings
47.7%
Success rate
12.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $31 | $22.80 | +35.96% | 18 | Jul 14, 2026 | |
| CELC Celcuity | Maintained: Buy | $165 | $88.38 | +86.69% | 15 | Jul 14, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | $40 | $31.48 | +27.06% | 5 | Jun 15, 2026 | |
| SMMT Summit Therapeutics | Maintained: Buy | $40 | $13.81 | +189.65% | 15 | Jun 1, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $38 → $35 | $11.47 | +205.14% | 5 | Jun 1, 2026 | |
| BCAX Bicara Therapeutics | Maintained: Buy | $42 | $27.76 | +51.30% | 2 | May 26, 2026 | |
| RLAY Relay Therapeutics | Maintained: Buy | $22 → $26 | $19.91 | +30.59% | 18 | May 25, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $68 → $58 | $16.26 | +256.70% | 9 | May 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $18 | $10.73 | +67.75% | 10 | May 4, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $125 | $115.77 | +7.97% | 20 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $14.75 | +137.29% | 3 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $54 | $32.13 | +68.07% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $17.69 | +69.59% | 7 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $71.85 | +25.26% | 3 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $7 | $3.69 | +89.70% | 20 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.79 | - | 17 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $10.86 | - | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 → $5 | $2.36 | +111.86% | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $5.11 | n/a | 23 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 → $1.5 | $2.10 | n/a | 20 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $63 → $51 | $8.01 | n/a | 25 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 13 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $4.49 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $65 | $52.86 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $16.24 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $68 | $3.95 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $5.38 | n/a | 1 | Apr 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $55.92 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $55 | $24.19 | n/a | 1 | Mar 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $38 | $26.81 | n/a | 1 | Jul 8, 2020 |
Syndax Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $31
Current: $22.80
Upside: +35.96%
Celcuity
Jul 14, 2026
Maintained: Buy
Price Target: $165
Current: $88.38
Upside: +86.69%
Damora Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $40
Current: $31.48
Upside: +27.06%
Summit Therapeutics
Jun 1, 2026
Maintained: Buy
Price Target: $40
Current: $13.81
Upside: +189.65%
Olema Pharmaceuticals
Jun 1, 2026
Maintained: Buy
Price Target: $38 → $35
Current: $11.47
Upside: +205.14%
Bicara Therapeutics
May 26, 2026
Maintained: Buy
Price Target: $42
Current: $27.76
Upside: +51.30%
Relay Therapeutics
May 25, 2026
Maintained: Buy
Price Target: $22 → $26
Current: $19.91
Upside: +30.59%
Janux Therapeutics
May 7, 2026
Reiterated: Buy
Price Target: $68 → $58
Current: $16.26
Upside: +256.70%
ORIC Pharmaceuticals
May 4, 2026
Reiterated: Buy
Price Target: $18
Current: $10.73
Upside: +67.75%
Kymera Therapeutics
Apr 30, 2026
Reiterated: Buy
Price Target: $125
Current: $115.77
Upside: +7.97%
Apr 29, 2026
Maintained: Buy
Price Target: $35
Current: $14.75
Upside: +137.29%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $54
Current: $32.13
Upside: +68.07%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $17.69
Upside: +69.59%
Feb 27, 2026
Reiterated: Buy
Price Target: $90
Current: $71.85
Upside: +25.26%
Feb 26, 2026
Reiterated: Buy
Price Target: $8 → $7
Current: $3.69
Upside: +89.70%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $1.79
Upside: -
Sep 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $10.86
Upside: -
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $10 → $5
Current: $2.36
Upside: +111.86%
Mar 27, 2025
Maintained: Buy
Price Target: $9
Current: $5.11
Upside: n/a
Mar 7, 2025
Maintained: Hold
Price Target: $3 → $1.5
Current: $2.10
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $63 → $51
Current: $8.01
Upside: n/a
Jan 9, 2025
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $37
Current: $4.49
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $65
Current: $52.86
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $15
Current: $16.24
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $68
Current: $3.95
Upside: n/a
Apr 26, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $5.38
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $30
Current: $55.92
Upside: n/a
Mar 30, 2021
Initiated Coverage: Buy
Price Target: $55
Current: $24.19
Upside: n/a
Jul 8, 2020
Initiated Coverage: Buy
Price Target: $38
Current: $26.81
Upside: n/a